Full history for every metric is available with a Kvantra account
Apollo Endosurgery, Inc. (APEN)
Key financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 64 | 61 | 51 | 42 | 63 | 77 | 77 |
| Operating profit | $m | -28 | -28 | |||||
| Net profit | $m | -27 | -46 | -27 | -23 | -25 | -40 | -40 |
| EPS reported | $ | -0.98 | -1.07 | |||||
| Operating cashflow per share | $ | -0.77 | -0.77 | |||||
| Capex per share | $ | 0.07 | 0.07 | |||||
| FCF per share | $ | -0.84 | -0.84 | |||||
| Free cash flow | $m | -34 | -34 | |||||
| Net debt | $m | 0 | -3 | |||||
| Book value equity | $m | 33 | 33 | |||||
| Book value per share | $ | 0.80 | 1.08 | |||||
| Number of shares | m | 40.65 | 30.24 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 12.43 | 17.79 | |||||
| P/S LTM | x | 5.27 | 7.54 | |||||
| P/FCF LTM | x | -11.92 | -17.05 | |||||
| EV/EBITDA LTM | x | -12.82 | -20.15 | |||||
| EV/Sales LTM | x | 5.27 | 7.50 | |||||
| Earnings Yield LTM | % | -9.83% | -9.80% | |||||
| FCF Yield | % | -8.39% | -5.87% | |||||
| Quality | ||||||||
| ROE | % | -122.23% | -84.92% | |||||
| ROIC | % | -30.59% | -30.59% | |||||
| Operating margin | % | -36.20% | -36.20% | |||||
| Gross margin | % | 55.20% | 55.20% | |||||
| FCF/Sales | % | -44.25% | -44.25% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +22.01% | +22.01% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -0.60 | -0.60 | |||||
| Net Debt/EBITDA | x | -0.00 | -0.00 | |||||
| EBIT/Net interest | x | -5.96 | -5.96 | |||||
| Net debt/market cap | % | 0.02% | -0.57% | |||||
| Net debt/Equity | x | 0.00 | -0.10 | |||||
| Gross debt/equity | x | 1.75 | 1.75 | |||||
Company overview
Apollo Endosurgery, Inc. is a medical technology firm specializing in the creation, development, and commercialization of advanced medical instruments. Among its products are the OverStitch and OverStitch Sx Endoscopic Suturing Systems, which empower physicians to perform advanced endoscopic procedures by suturing and securing tissue approximation via a flexible endoscope. The company also features the Orbera intragastric balloon system, available under brands such as Orbera Intragastric Balloon System, BIB, and Orbera365 Managed Weight Loss System. This system aids in weight management by decreasing stomach capacity and slowing gastric emptying, thereby encouraging reduced food intake. Additionally, it provides the X-Tack Endoscopic HeliX Tacking System, a suture-based device designed for repairing defects in both the upper and lower gastrointestinal tract. Its medical solutions are distributed to various healthcare providers, including hospitals, outpatient surgical centers, clinics, and individual physicians, across the United States, Australia, Costa Rica, and several European nations. Founded in 2005, Apollo Endosurgery, Inc. maintains its headquarters in Austin, Texas.
Similar companies
- OrthoPediatrics Corp.
- LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.
- Nanjing Vishee Medical Technology Co., Ltd
- Ningbo David Medical Device Co., Ltd.
- Guangdong Biolight Meditech Co., Ltd.
- China Isotope & Radiation Corporation
- SS Innovations International, Inc.
- Wuhan Easy Diagnosis Biomedicine Co.,Ltd.
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Apollo Endosurgery, Inc. (APEN)
Apollo Endosurgery, Inc. is a medical technology firm specializing in the creation, development, and commercialization of advanced medical instruments. Among its products are the OverStitch and OverStitch Sx Endoscopic Suturing Systems, which empower physicians to perform advanced endoscopic procedures by suturing and securing tissue approximation via a flexible endoscope. The company also features the Orbera intragastric balloon system, available under brands such as Orbera Intragastric Balloon System, BIB, and Orbera365 Managed Weight Loss System. This system aids in weight management by decreasing stomach capacity and slowing gastric emptying, thereby encouraging reduced food intake. Additionally, it provides the X-Tack Endoscopic HeliX Tacking System, a suture-based device designed for repairing defects in both the upper and lower gastrointestinal tract. Its medical solutions are distributed to various healthcare providers, including hospitals, outpatient surgical centers, clinics, and individual physicians, across the United States, Australia, Costa Rica, and several European nations. Founded in 2005, Apollo Endosurgery, Inc. maintains its headquarters in Austin, Texas.
- OrthoPediatrics Corp.
- LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.
- Nanjing Vishee Medical Technology Co., Ltd
- Ningbo David Medical Device Co., Ltd.
- Guangdong Biolight Meditech Co., Ltd.
- China Isotope & Radiation Corporation
- SS Innovations International, Inc.
- Wuhan Easy Diagnosis Biomedicine Co.,Ltd.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free